Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Not Confirmed
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Not Confirmed
Not Confirmed
05-08 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Fall Technical MeetingFall Technical Meeting
Industry Trade Show
Not Confirmed
05-07 October, 2025
The MedTech ConferenceThe MedTech Conference
Industry Trade Show
Not Confirmed
05-08 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
09 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizal-showcases-robust-portfolio-of-lung-cancer-studies-at-2025-wclc-302550606.html
02 Jul 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219839
02 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizals-zegfrovy-sunvozertinib-receives-fda-accelerated-approval-as-the-only-targeted-oral-treatment-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302497351.html
19 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizal-completes-enrollment-for-its-phase-iii-pivotal-study-of-sunvozertinib-vs-platinum-doublet-in-treatment-naive-nsclc-patients-with-egfr-exon20-insertional-mutations-302486187.html
12 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizal-showcases-two-first-in-class-therapies-in-hematologic-malignancies-at-eha-and-icml-2025-302480124.html
26 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/dizal-to-highlight-its-portfolio-advances-in-hematologic-malignancies-and-lung-cancer-at-asco-2025-302465161.html
ABOUT THIS PAGE